VIVO Cannabis™ Announces Second Quarter 2020 Results

  1. Net revenue of $9.4 million – an increase of 15% over Q1 2020 and 79% over Q2 2019
  2. Achieved 68% Ontario retail market share in the concentrates category, including first-to-market shatter by Fireside™ X
  3. Entered product supply and clinical services agreements with Medical Cannabis by Shoppers™
  4. Canna Farms™ is the fourth most recognized cannabis brand, according to recent Brightfield Group independent survey
  5. Largest export shipment to Australia occurred during the quarter

– VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) (“VIVO“or the “Company“)today released its second quarter 2020 financial and operating results.

– VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) (“VIVO“or the “Company“)today released its second quarter 2020 financial and operating results.

Management Commentary

“This is our fifth consecutive quarter of sequential sales growth. We are pleased with our quarterly results, with Q2 2020 sales increasing 79% over the prior year quarter, while sales, general and administrative expenses decreased 18% over the same period,” said Barry Fishman, CEO of VIVO. “Notable achievements include the expansion of our leadership position in the concentrates category across several provinces, the introduction of a first-to-market shatter by Fireside™ X, and the naming of Canna Farms™ as the fourth most recognized cannabis brand among Canadian cannabis consumers in a recent Brightfield Group survey. We also advanced several key medical cannabis initiatives in order to position the business for future success, including entering into product supply and clinical services agreements with Medical Cannabis by Shoppers™.”

Financial Summary

Gross and net revenue for Q2 2020 were $12.7 million and $9.4 million, respectively. On a net basis this represents a 15% increase quarter-over-quarter as compared to Q1 2020, driven largely by successful sales of VIVO’s Cannabis 2.0 products. When compared to Q2 2019, net revenue grew by approximately 79%.

Concentrates made up over half of VIVO’s cannabis sales revenue during the quarter, a testament to the Company’s strategic decision to be a leader in that space. This was offset by lower flower sales, resulting from decreased market demand in the wake of the COVID-19 pandemic.

VIVO continued to sustain top-tier prices for its medical and adult-use dry flower products, with a net average selling price (net of excise) of $6.07 per gram in Q2 2020.

The Company purchased third-party extraction inputs in Q2 2020. The internal extraction suite at its Vanluven facility is now able to provide these inputs and VIVO expects the gross margin on its vape and extract products will improve significantly.

Sales, general and administrative expenses were $4.7 million in Q2 2020, compared to $5.5 million in the first quarter, a reduction of 15%.

The Company’s adjusted EBITDA(1) was ($2.2) million for the quarter, an improvement of $0.4 million over the first quarter of 2020. VIVO’s Q2 2020 adjusted EBITDA(1) derived from Domestic Cannabis Operations was ($1.8) million. The additional ($0.4) million of adjusted EBITDA(1) in the quarter was related to Growth Initiatives (International Operations and New Product Development), which represent current investments that are expected to drive future profitable sales beyond 2020.

VIVO continues to maintain a healthy balance sheet through prudent management of operational expenses and a measured approach to capital expenditures. During Q2 2020, VIVO repurchased certain of its outstanding 6% unsecured convertible debentures in the aggregate principal amount of $10.9 million, for a discounted purchase price of $10.1 million (plus accrued and unpaid interest), leaving remaining debentures in the aggregate principal amount of $27.1 million outstanding. As a result, the Company will save approximately $1.35 million in interest and principal. Cash and cash equivalents (including short term investments but excluding strategic equity investments) as at June 30, 2020 were $22.2 million.

Key Performance Indicators

KPI
(P&L amounts in millions)
Q2 2020Quarter-over-
Quarter Change
Q1 2020
Gross Revenue$12.711%$11.5
Net Revenue$9.415%$8.2
SG&A$4.7(15%)$5.5
Adjusted EBITDA (1)($2.2)15%($2.6)
Cash and equivalents$22.2(37%)$35.2
Active patients (2)25,50019%21,444
Net flower price per gram$6.07(9%)$6.67
Product formats814%7
(1)      Adjusted EBITDA is not a measure of financial performance under IFRS. For the Company’s definition of Adjusted EBITDA, see the Company’s management’s discussion and analysis for the three and six months ended June 30, 2020, available under the Company’s profile at www.sedar.com.
(2)    Represents active patients (as of the end of the quarter) who purchase medical cannabis directly from the Company, including new temporary six-month extensions post March 13, 2020 based on Health Canada’s amendment due to COVID-19.

Business Update

VIVO remains focused on executing against its four strategic priorities. In the first half of 2020, the Company has made significant progress in enhancing supply and production capabilities, expanding its customer network, increasing product innovation and accelerating its international medical business. VIVO believes that focusing on these four priorities will generate long-term shareholder value and accelerate the path to profitability.

1.     Enhance Supply and Production Capabilities 

VIVO continues to adhere to a measured and disciplined approach to capacity expansion and production capabilities by ensuring initiatives pursued are cost effective and will be capable of meeting growing patient and consumer demand.

  • Canna Farms’ 10,000 square foot Phase 5 expansion received all necessary Health Canada approvals in the quarter. Operational rooms are being fully utilized for storage and processing, and planting has commenced in the cultivation areas, using a two-tiered growing system.
  • Commissioning of the Vanluven facility’s ethanol extraction suite is complete and commercial production is underway. The resulting high quality, low production-cost resins and distillates will be used as inputs for VIVO’s oils, vape cartridges, and other Cannabis 2.0 products, such as the first Canadian-launched shatter by Fireside™ X.
  • Following planting in the first quarter of 2020, the seasonal airhouses at the Kimmetts facility now contain over 10,000 healthy plants, most of them over seven feet tall.

2.     Create a Broad and Loyal Customer Network

VIVO has a strong portfolio of brands in both the medical and adult-use markets. Its Canna Farms™ brand is one of the leading brands in the industry, known for producing award-winning, BC indoor-grown, craft cannabis flower and newly launched solvent-less extracts and edibles.

  • VIVO continued to maintain top-tier net pricing of $6.07 per gram of dry flower and implemented some price reductions to stay competitive within the premium market segment.
  • VIVO entered into a product supply agreement and a clinic services agreement with Medical Cannabis by Shoppers™. Under the terms of the supply agreement, VIVO’s licensed producers will offer a broad portfolio of Canna Farms™ and Beacon Medical™ branded medical cannabis products through the Medical Cannabis by Shoppers™ online sales platform to patients across Canada, including its latest Cannabis 2.0 offerings such as chocolates and extracts. Under the terms of the clinic services agreement, VIVO’s subsidiary, Harvest Medicine, will provide cannabis education services to patients who are appropriate candidates for cannabinoid-based products and provide consulting services to the Medical Cannabis by Shoppers™ Cannabis Care team.
  • VIVO entered into a collaboration agreement with Veterans’ House (“Veterans’ House“), under which the Company will provide sponsorship and support to joint programs for Canadian Armed Forces veterans. Veterans’ House is a federally registered non-profit organization that provides veterans suffering from mental illness and operational stress injuries, such as post-traumatic stress disorder, access to counseling and peer support programs.
  • In Q2 2020, VIVO began shipping products under its Canadian Bud Collection™, brand, which launched in Q1 2020 and is directed at the popular value segment of the market.
  • After temporarily realigning Harvest Medicine’s resources to provide patient-focused services through its telemedicine platform, HMED Connect, at the outset of the COVID-19 pandemic, Harvest Medicine clinics are now “patient ready”, with precautions in place to accommodate walk-in patients and help stop the spread of COVID-19, while continuing to offer patients online options to receive services.

3.     Build an Innovation-Driven Branded Organization

VIVO has a strong commitment to pursuing innovation throughout its value chain. The Company is also using its robust data insights as a foundation for the development of novel products with a strong competitive edge and high margins.

  • During Q2 2020, VIVO made initial shipments of its Fireside X shatter product to several provincial wholesalers, including in British Columbia, where the provincial wholesaler sold its entire purchase within the first week. This is the fifth significant concentrates product format launched by VIVO, following Fireside vape cartridges, and Canna Farms’ bubble hash, kief and live rosin.
  • This month VIVO introduced Beacon Medical softgel capsules, available through its Canna Farms on-line medical marketplace. Beacon softgel capsules provide patients with a convenient format to ingest cannabis in a precise-dosed format, increasing choice for the Company’s more than 25,000 registered patients.
  • Subsequent to the signing of an exclusive agreement with Vertosa Inc., an infusion technology company based in Oakland, California, for Canadian production rights, Vertosa’s equipment has been installed at the Vanluven facility. VIVO expects to begin production of active emulsions using this technology for the cannabis beverage market in the coming months.
  • VIVO advanced into the next stage of product development with partner, Pharmascience Inc., a global pharmaceutical company based in Montreal, Quebec, for a unique line of specific medical cannabis formulations produced under pharmaceutical quality standards. VIVO believes that a significant catalyst to increased medical cannabis use is the introduction of new medical-grade, precise-dosed, stable formulations, which the partnership with Pharmascience is intended to target. The first products from this partnership are expected to be introduced in the Canadian market by the end of Q1 2021.

4.     Accelerate International Medical Business Growth 

VIVO continues to pursue its international expansion strategy, leveraging its experience and leadership to enter new high-growth markets. The Company’s initial focus is on the German and Australian markets, which, combined, have a population of over 100 million people.

  • VIVO’s Australian business continues to rapidly advance, achieving record sales in Q2 2020. Australia’s Therapeutics Goods Administrator (TGA) reported a record number of new patient approvals in July of 2020 and triple digit growth in patient approvals year over year. VIVO is well positioned to capitalize on this rapidly growing market.
  • VIVO continued to advance its European expansion strategy through its partnership with Linneo Health, a Spanish-based EU-GMP certified supplier of pharma-grade cannabis. VIVO’s subsidiary, Beacon Medical Germany, is expecting final approval of Linneo product for import to Germany in late 2020.
  • Beacon Medical Germany was granted a narcotics licence in Germany, and is awaiting receipt of an import licence, the final permit necessary to facilitate imports from VIVO’s Vanluven facility and from other non-EU sources. EU-GMP certification of VIVO’s Vanluven Facility continues to advance, with a follow-up audit having recently been completed. The follow-up audit is an important step towards EU GMP-certification and is a requirement to import medical cannabis products from Canada for sale in Germany and other European countries.

COVID-19 Update

VIVO continues to monitor COVID-19 developments and has implemented enhanced personal safety and sanitation protocols. VIVO’s production facilities are continuing operations and, to the Company’s knowledge, there have been no confirmed cases of COVID-19 among Company personnel. The Napanee and Hope facilities have extended hours and staggered shifts to facilitate physical distancing and ensure a safe work environment.

Q2 2020 Results Conference Call and Webcast

DATE:Monday, August 17, 2020
TIME:11:00 a.m. ET
DIAL-IN NUMBER:647-427-7450 or 1-888-231-8191
CONFERENCE ID:8762205
LIVE WEBCAST:https://bit.ly/31UGPPP

About VIVO Cannabis™

VIVO Cannabis™ is recognized for trusted, premium cannabis products and services. It holds production and sales licences from Health Canada and operates world-class indoor and seasonal airhouse cultivation facilities with proprietary plant-growing technology in Hope, British Columbia and Napanee, Ontario. VIVO has a collection of premium brands, each targeting different customer segments, including Canna Farms™, Beacon Medical™, Fireside™, Fireside-X™, Lumina™ and Canadian Bud Collection™. The Company is expanding its production capabilities and distribution network. Harvest Medicine, VIVO’s patient-centric, scalable network of medical cannabis clinics, has serviced over 100,000 patient visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia. The Company has a healthy balance sheet and is well-positioned to accelerate its path to profitability. For more information visit: www.vivocannabis.com.

Instagram
LinkedIn
Facebook
Twitter

Disclaimer for Forward-Looking Information

All dollar amounts in this news release are in Canadian dollars. Certain statements in this news release are forward-looking statements, which are statements that are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of VIVO and its management regarding the future. Forward-looking statements in this news release include statements regarding: the Company’s expected catalysts to deliver profitable growth, including entry into international markets and the development and launch of innovative products and services, and the financial impact thereof; the Company’s expectation that focusing on its four strategic priorities will generate long-term shareholder value and accelerate the path to profitability; the factors that VIVO believes will drive significant growth in medical cannabis utilization; the ability of the Company’s growth initiatives to drive future profitable sales beyond 2020the expected timing of shipment of active emulsions from the Vanluven facility; that certain products offered by the Company will be sold through the Medical Cannabis by Shoppers™ platform; that the products generated from the Company’s partnership with Pharmascience Inc. are intended to maximize therapeutic benefit to patients; and, the expected timing of the introduction of Linneo products for import to Germany. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the medical cannabis market may not grow to the extent, within the time, or for the reasons expected by the Company; that the COVID-19 pandemic may last longer and have a more significant impact on the Company’s operations, the Canadian cannabis industry, or the global economy generally, than currently expected; that the Company faces competition against new market entrants and participants; that the Company may not be able to launch new products in the time expected or at all and that patients may not receive the expected benefits therefrom; that the Company may not be able to achieve competitive margins; that new products, if launched, may not be accepted by the market or may become subject to product liability claims; that the Company may not be able to obtain necessary licences; that demand for the Company’s products may not meet management’s expectations; that the timing of EU-GMP certification may be delayed due to travel restrictions related to the COVID-19 pandemic or otherwise; that the Company may be unable to retain its key talent; that the Company may not be able to execute on its strategic partnerships; that the Company may not obtain any other necessary regulatory approvals as required from time to time; that the Company may be unable to protect its intellectual property; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully, and the more extensive risk factors included in the Company’s management’s discussion and analysis for the three and six months ended June 30, 2020, which is available on SEDAR, in evaluating the forward-looking statements contained in this news release, and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. The forward-looking statements in this news release are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

SOURCE NEWSWIRE

CANDLR VIVO INTERNATIONAL COMPANY PROFILE +

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s